The purpose of the study is to find out whether the ultra‑long‑acting injection of these two medicines works at least as well as the standard long‑acting version in keeping the virus low and is safe for participants.

Participants will receive an injection at the beginning of the study and then will come back for additional injections at regular intervals over a period of about two years. During the visits, simple blood tests will be done to measure the amount of virus (viral load) and to count immune cells called CD4 cells, which help the body fight infections. The study will also watch for any side effects or reactions to the injections.

The primary purpose of the study is to determine whether this approach can be safely made and given to patients and tolerated without serious side effects. After the cells are prepared in a laboratory, participants receive a single infusion and are then monitored over several months with routine health checks, breathing tests, and blood work to see how well the treatment is tolerated and whether lung function improves. Simple explanations are provided for any medical terms used, such as describing the modified cells as “engineered immune cells” and the virus used for gene delivery as a “carrier that safely introduces new instructions into the cells.”

The purpose of the trial is to determine whether this combination can achieve durable immunological control of the virus when antiretroviral therapy is stopped. After receiving the study infusions, participants will pause their regular ART under close medical supervision and will have regular blood tests to monitor viral levels and immune‑cell counts; if the virus rises above predefined thresholds or immune cells fall, treatment will be restarted.

During the entire study period, participants will be monitored for any side effects or laboratory changes, and any serious problems will be reported to the study team, with follow‑up extending for several months after the therapy interruption.

The purpose of the study is to determine whether reducing or stopping the medication after the disease has been quiet for at least a year changes the chance of a worsening episode compared with continuing the same dose.

Participants who meet the criteria will be randomly assigned to either keep the same amount of medicine (stable dose) or to slowly lower the amount and eventually stop (tapered). Over the following 12 months they will attend regular check‑ups where doctors will look for signs of a flare, which means a noticeable increase in joint pain, swelling or loss of movement, indicating the disease is no longer in an inactive disease state. If a flare occurs, treatment can be restarted to bring the condition back under control, and safety and any side effects are recorded throughout the year.

Participants will be randomly assigned to receive either a low‑dose, a high‑dose, or a placebo (a harmless substance that looks the same as the vaccine) in a series of injections spread over several weeks. After the dosing period, they will be followed throughout the grass pollen season and asked to note each day how severe their symptoms are and whether they need any allergy medication. The key result the study will look at is the average daily Combined Symptom and Medication Score (CSMS), a single number that combines the intensity of symptoms with the amount of rescue medicine used, to see how well the vaccine works compared with the placebo. Safety checks will be performed throughout the study.

Participants will undergo a single prick test session where the drops are applied, and the size of the raised bump (called a wheal) is measured in square millimeters. A larger wheal indicates a stronger reaction. Safety is checked by watching for any uncomfortable feelings at the test site or broader symptoms, which are recorded as adverse events. The study also uses the ALEX technique to profile the allergen, which helps to understand which specific proteins cause the reaction. The overall process takes a short visit, and the results will help choose the best concentration of the extract for future diagnostic use.

The purpose of the research is to see whether the drug can be given safely and is well tolerated by people who have just been diagnosed with the disease. Participants will receive a subcutaneous injection of the medication using a pre‑filled syringe at regular intervals over a period of about one year, with clinic visits scheduled to monitor health and collect information.

During the study, doctors will track changes in a score called the BPDAI, which measures the number and size of blisters and the amount of skin affected. They will also ask participants to rate their itch on a simple 0‑10 scale, evaluate the impact on daily life and mood, and record any use of other skin‑care treatments. These assessments help determine how the drug affects the skin condition and overall well‑being.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The study follows participants for an extended period during which they receive regular injections of the medication and attend scheduled visits for health checks. At each visit, researchers record any side effects, which are referred to as adverse events, and collect questionnaire responses that measure changes in eye muscle strength, daily activity ability, and overall quality of life. The overall aim is to determine whether the medication is safe and tolerable for people living with this eye‑related form of myasthenia gravis.

Participants will receive a series of injections over a period of several weeks, with regular visits to the clinic where doctors will ask about eye symptoms, quality of life, and ability to perform daily activities. Simple questionnaires will be used to measure changes in eye muscle strength and overall well‑being. The study will also monitor any side effects that may occur during the treatment period.

Participants will take one hard capsule each day for about six months while keeping a simple diary of any swelling episodes, any other health problems, and any use of emergency treatment. Regular check‑ins with study staff will be scheduled to review the diary, assess safety, and record any side effects, known as adverse events. The overall design is open‑label and single‑arm, meaning all participants receive the same medication and know they are receiving the active treatment.

Participants will first undergo screening tests, then receive a single infusion of the modified cells. After the infusion, they will have regular clinic visits where blood samples are drawn and simple health questionnaires are completed to monitor for any side effects and to check if platelet or red‑cell numbers improve. Follow‑up continues for several months to observe how long any benefit lasts and to record any additional medical support needed. Throughout the study, doctors will watch for any unusual lab results or symptoms and will provide standard medical care as needed.

Participants will receive one tablet each day for about nine months. Throughout the study they will visit the clinic regularly, where health care staff will collect a urine sample, usually the first morning urine, and perform a simple test that compares the protein level to a normal waste product to see how much protein is present. Blood samples will also be taken to understand how the body absorbs and clears the medication. Doctors will monitor safety by checking for any side effects, routine lab results, and vital signs during the visits.

People who join the study will apply the cream to affected skin areas twice each day for about four months. During this time they will attend regular clinic visits where doctors will look at the skin and record changes using a scoring system called mSWAT, which rates how much of the skin is involved and how severe the patches are. Participants will also answer simple questionnaires about itching (called pruritus) and how the skin condition affects daily life. Small skin samples may be taken to explore how the medicine works, and a gentle test may be performed to see if the skin barrier improves. The study ends after the treatment period, and the collected information helps researchers understand whether the cream is safe and how well it works for this condition.